HLB Pharmaceutical announced on the 18th that it received the Grand Prize in the Innovative Products Pharmaceutical Category at the ‘6th Korea Small Giants Awards 2023’ hosted by the Korea Small Giants Association.
Kim Man-gyu, Vice President of HLB Pharmaceutical, who won the Grand Prize in the Innovative Pharmaceutical Products category at the '6th Korea Small Giants Awards 2023,' is posing for a commemorative photo. [Photo by HLB Pharmaceutical]
The Grand Prize in the Innovative Products Category is awarded to companies that possess world-first or domestic-first patented technologies or innovative products. HLB Pharmaceutical was highly evaluated for developing the blockbuster thrombosis treatment 'Apixaban (brand name Eliquis)' as the world’s first long-acting injectable improved new drug, which led to receiving this award.
HLB Pharmaceutical’s long-acting injectable formulation containing Apixaban (project name HP-P024) currently holds related patents for manufacturing compositions and methods in Korea, Japan, China, and Europe. In January, it received approval for a Phase 1 clinical trial plan (IND) for this project from the Ministry of Food and Drug Safety.
Lee Sang-hwi, Head of Central Research Institute at HLB Pharmaceutical, said about HP-P024, “We developed a long-acting injectable improved new drug to reduce risks such as gastrointestinal bleeding, which is a known drawback of Eliquis, low medication adherence, and the risk of stroke occurrence upon discontinuation of medication.”
Park Jae-hyung, CEO of HLB Pharmaceutical, stated, “Global partnering discussions regarding our proprietary long-acting injectable platform technology SMEB are actively underway. Since it attracted significant attention from scholars at the Controlled Release Society (CRS) conference held in the U.S. last July, we expect to deliver tangible business results in the near future.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
